CA-NETAPP
16.3.2021 15:02:14 CET | Business Wire | Press release
Less than a year after joining global software leader NetApp (NASDAQ: NTAP) as its President, César Cernuda has announced changes to the go-to-market (GTM) model and global sales organization that will help steer the company into its cloud-led future.
Cernuda is instituting a customer- and partner-centric strategic and operational evolution that will allow NetApp to move to a customer engagement model focused on driving deeper specialization and delivering hybrid cloud expertise powered by digitization. The changes will see the company ramp up its efforts to drive consistency and simplicity across its global sales organization and more aggressively address key markets and segments while reaching new customers and partners.
“With today’s relentless pace of change, speed is the new scale. And that’s what organizations are demanding as they try to put their data to work to keep innovating and stay ahead of the digital curve,” said César Cernuda. “We are implementing these changes to better serve their needs. We will soon deliver a personalized, data-driven engagement model that allows our current and future customers to move at warp speed and aligns with the new way they want to engage with their solution partners.”
The evolution of NetApp’s sales organization will also result in changes and additions to the sales leadership team, effective May 1, 2021:
- NetApp veteran and former SVP, Globals, Verticals, and Pathways, Rick Scurfield will serve in the company’s newly established role of Chief Commercial Officer . Scurfield will be responsible for building a new GTM motion and strategy including direct sales and channel coverage and will drive the transformation of NetApp’s digital and virtual sales teams and Sales Operations to better enable NetApp’s sales force and worldwide partnerships. Scurfield has led winning sales organizations for more than 20 years, most recently growing and leading sales teams supporting NetApp’s largest global accounts, vertical segments, global pathways, and the U.S. Public Sector.
- Max Long , former SVP, Chief Customer Officer at Adobe, will be joining NetApp as the company’s new SVP, North America . Leveraging his 30+ years of experience building high-performance sales teams and leading business transformations. Long will continue the focus on aligning NetApp’s business objectives in the U.S. and Canada driven by our customer’s business requirements. He will lead direct sales, channel sales, and demand generation teams.
- Alex Wallner, also a NetApp veteran who most recently served as SVP, Worldwide Enterprise and Commercial Field Operations, will take on the newly created role of SVP, International . Wallner will lead the execution of all GTM activities for the EMEA, APAC and Latin America regions. Focusing on increasing the footprint of NetApp as the partner-of-choice for our international customers, he and his team will help customers address their data challenges with hybrid multi-cloud solutions including NetApp’s data center architectures and superior cloud software portfolio.
“Rick’s and Alex’s proven leadership and in-depth knowledge of our industry, our customers and our partners combined with Max’s track record of leading enterprise sales teams to success at scale will be instrumental in helping organizations everywhere unlock the best of today’s hybrid multi-cloud world, wherever they are on their digital transformation journey—on premises or in any cloud,” added Cernuda.
The evolution of the NetApp data-driven GTM model and cloud-led sales organization is expected to be a continuous process starting in Q1 FY22.
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005711/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom